ISRAELI-FOUNDED Teva Pharma Australia joined the Generic and Biosimilar Medicines Association (GBMA) recently.
Independent Chair Jane Halton shared, "Teva's supply chain delivers to patients globally and is committed, as we are, to do more to protect Australian patients against preventable medicine shortages, while delivering fiscal relief to the health budget and protecting patients against the rising cost of living".
Teva Vice President, APAC Cluster Head and General Manager ANZ, Jim Margaritis, said, "Teva has significant overseas experience linking public health initiatives to the savings generated by cost-effective treatments, and looks forward to contributing to GBMA's efforts in implementing policies that support both patients and their clinicians".
Halton added, "while we stand before a significant shift in medicine policy, more can be achieved, as biosimilar medicines remain an untapped resource that could be utilised to offset budget initiatives aimed at supporting patients".
CEO of the GBMA Marnie Peterson said protecting patients against the rising cost of living and avoidable medicine shortages further underscored the shared objectives of Teva and the GBMA.
"Teva, like all GBMA members, has marked a milestone in GBMA's five-year Strategic Agreement, creating stockholding buffers of four to six months," she said.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Jul 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Jul 23
